

# Jeffrey I Weitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2918408/publications.pdf>

Version: 2024-02-01

520  
papers

63,796  
citations

1294

109  
h-index

906

241  
g-index

538  
all docs

538  
docs citations

538  
times ranked

38014  
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
2	Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet</i> , The, 2014, 383, 955-962.	6.3	3,942
3	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	1.2	2,392
4	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 799-808.	13.9	1,915
5	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1330-1393.	1.0	1,576
6	Low-Molecular-Weight Heparins. <i>New England Journal of Medicine</i> , 1997, 337, 688-698.	13.9	1,520
7	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	13.9	1,419
8	Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer. <i>Thrombosis and Haemostasis</i> , 2000, 83, 416-420.	1.8	1,417
9	Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2018, 378, 615-624.	13.9	1,237
10	A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 1996, 334, 677-681.	13.9	1,157
11	Apixaban for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 699-708.	13.9	1,116
12	A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 1999, 340, 901-907.	13.9	1,052
13	Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. <i>Circulation</i> , 2002, 105, 1650-1655.	1.6	1,040
14	Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.. <i>Journal of Clinical Investigation</i> , 1990, 86, 385-391.	3.9	1,036
15	Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	13.9	858
16	Parenteral Anticoagulants. <i>Chest</i> , 2012, 141, e24S-e43S.	0.4	839
17	Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 1998, 129, 997.	2.0	835
18	Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review. <i>Circulation</i> , 1996, 94, 3026-3049.	1.6	755

#	ARTICLE	IF	CITATIONS
19	Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism. <i>New England Journal of Medicine</i> , 1997, 337, 657-662.	13.9	731
20	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018, 378, 2191-2201.	13.9	730
21	Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2003, 349, 631-639.	13.9	728
22	Accuracy of clinical assessment of deep-vein thrombosis. <i>Lancet, The</i> , 1995, 345, 1326-1330.	6.3	705
23	Parenteral Anticoagulants. <i>Chest</i> , 2008, 133, 141S-159S.	0.4	674
24	Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2363-2371.	1.1	659
25	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 1211-1222.	13.9	577
26	Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. <i>Blood</i> , 2005, 105, 1734-1741.	0.6	512
27	Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 365, 2167-2177.	13.9	512
28	Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. <i>New England Journal of Medicine</i> , 2015, 372, 232-240.	13.9	497
29	Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development. <i>Clinical Pharmacokinetics</i> , 2009, 48, 1-22.	1.6	466
30	The Postthrombotic Syndrome: Evidence-Based Prevention, Diagnosis, and Treatment Strategies. <i>Circulation</i> , 2014, 130, 1636-1661.	1.6	446
31	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet, The</i> , 2000, 355, 1936-1942.	6.3	419
32	Safety of Withholding Heparin in Pregnant Women with a History of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2000, 343, 1439-1444.	13.9	409
33	Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 7734-7738.	3.3	406
34	Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1977-1984.	1.1	379
35	Medical device-induced thrombosis: what causes it and how can we prevent it?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S72-S81.	1.9	374
36	Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. <i>Thrombosis and Haemostasis</i> , 1995, 74, 606-611.	1.8	351

#	ARTICLE	IF	CITATIONS
37	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
38	A Test in Context: D-Dimer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2411-2420.	1.2	342
39	Prosthetic Heart Valve Thrombosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2670-2689.	1.2	332
40	Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1612.	2.6	326
41	The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor $\kappa$ B and Mitogen-activated Protein Kinase Pathways. <i>Journal of Experimental Medicine</i> , 2002, 196, 565-577.	4.2	325
42	Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells. <i>Blood</i> , 1999, 94, 959-967.	0.6	324
43	Antiplatelet Drugs. <i>Chest</i> , 2012, 141, e89S-e119S.	0.4	318
44	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010, 104, 633-641.	1.8	311
45	New Antithrombotic Drugs. <i>Chest</i> , 2012, 141, e120S-e151S.	0.4	284
46	Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. <i>Biochemistry</i> , 1990, 29, 8424-8429.	1.2	266
47	New Anticoagulants. <i>Circulation</i> , 2010, 121, 1523-1532.	1.6	262
48	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	1.2	257
49	CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 1044-1048.	3.3	251
50	Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. <i>Lancet</i> , The, 2002, 359, 294-302.	6.3	251
51	New Antithrombotic Drugs. <i>Chest</i> , 2008, 133, 234S-256S.	0.4	235
52	Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. <i>Critical Care</i> , 2012, 16, R151.	2.5	225
53	Strain history dependence of the nonlinear stress response of fibrin and collagen networks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 12197-12202.	3.3	224
54	Characterization of the stress-inducing effects of homocysteine. <i>Biochemical Journal</i> , 1998, 332, 213-221.	1.7	221

#	ARTICLE	IF	CITATIONS
55	Antithrombotic Therapy During Percutaneous Coronary Intervention. <i>Chest</i> , 2004, 126, 576S-599S.	0.4	220
56	Venous thrombosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15006.	18.1	216
57	Sensitivity and Specificity of a Rapid Whole-Blood Assay for D-Dimer in the Diagnosis of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 1998, 129, 1006.	2.0	215
58	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
59	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205
60	A Novel and Rapid Whole-Blood Assay for D-Dimer in Patients With Clinically Suspected Deep Vein Thrombosis. <i>Circulation</i> , 1995, 91, 2184-2187.	1.6	203
61	Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors. <i>Circulation</i> , 1998, 97, 544-552.	1.6	198
62	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018, 20, 1231-1242.	0.7	194
63	Therapeutic strategies for thrombosis: new targets and approaches. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 333-352.	21.5	188
64	Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1428-1436.	1.9	181
65	Management of Suspected Deep Venous Thrombosis in Outpatients by Using Clinical Assessment and D-dimer Testing. <i>Annals of Internal Medicine</i> , 2001, 135, 108.	2.0	179
66	Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 366, l4363.	2.4	177
67	Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 2187-2191.	1.9	175
68	New anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1843-1853.	1.9	172
69	Coagulation Assays. <i>Circulation</i> , 2005, 112, e53-60.	1.6	170
70	New Anticoagulants for Treatment of Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 380-386.	1.1	168
71	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	1.8	165
72	A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancellous Bone in Rats. <i>Blood</i> , 1997, 89, 3236-3242.	0.6	163

#	ARTICLE	IF	CITATIONS
73	An Evaluation of D-Dimer in the Diagnosis of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2006, 144, 812.	2.0	159
74	More Effective Suppression of Hemostatic System Activation in Patients Undergoing Cardiac Surgery by Heparin Dosing Based on Heparin Blood Concentrations rather than ACT. <i>Thrombosis and Haemostasis</i> , 1996, 76, 0902-0908.	1.8	157
75	New anticoagulants. <i>Blood</i> , 2005, 105, 453-463.	0.6	155
76	Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies. <i>Thrombosis and Haemostasis</i> , 2013, 110, 205-212.	1.8	155
77	Overview of the New Oral Anticoagulants. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1056-1065.	1.1	155
78	Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). <i>Thrombosis and Haemostasis</i> , 2013, 109, 769-786.	1.8	154
79	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	1.8	154
80	New Anticoagulant Drugs. <i>Chest</i> , 2001, 119, 95S-107S.	0.4	153
81	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	1.2	150
82	Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin. <i>Thrombosis and Haemostasis</i> , 1994, 71, 300-304.	1.8	150
83	Assays for Measuring Rivaroxaban: Their Suitability and Limitations. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 673-679.	1.0	148
84	The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem. <i>Acta Biomaterialia</i> , 2019, 94, 2-10.	4.1	148
85	Patients with severe sepsis vary markedly in their ability to generate activated protein C. <i>Blood</i> , 2004, 104, 3958-3964.	0.6	147
86	Plasma fibronectin supports hemostasis and regulates thrombosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 4281-4293.	3.9	147
87	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 130.	3.8	146
88	Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. <i>Thrombosis and Haemostasis</i> , 2010, 104, 642-649.	1.8	144
89	Abelacimab for Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 609-617.	13.9	143
90	New Anticoagulant Drugs. <i>Chest</i> , 2004, 126, 265S-286S.	0.4	142

#	ARTICLE	IF	CITATIONS
91	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782.	1.8	142
92	Idarucizumab. <i>Circulation</i> , 2015, 132, 2412-2422.	1.6	141
93	Characterization of a Mouse Model for Thrombomodulin Deficiency. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1531-1537.	1.1	138
94	Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. <i>Blood</i> , 2014, 123, 2102-2107.	0.6	136
95	Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. <i>Lancet Haematology</i> , 2016, 3, e379-e387.	2.2	136
96	Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 743-749.	1.9	133
97	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	1.8	132
98	Direct thrombin inhibitors. <i>Thrombosis Research</i> , 2002, 106, V275-V284.	0.8	131
99	Direct Thrombin Inhibitors in Acute Coronary Syndromes. <i>Circulation</i> , 2002, 105, 1004-1011.	1.6	128
100	Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2544-2553.	1.1	127
101	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. <i>Clinical Therapeutics</i> , 2015, 37, 2506-2514.e4.	1.1	124
102	Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. <i>Nuclear Medicine and Biology</i> , 2000, 27, 289-297.	0.3	122
103	Milvexian for the Prevention of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2021, 385, 2161-2172.	13.9	122
104	A Diagnostic Strategy Involving a Quantitative Latex D-Dimer Assay Reliably Excludes Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2003, 138, 787.	2.0	120
105	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007, 28, 880-913.	1.0	119
106	A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. <i>Journal of Internal Medicine</i> , 1998, 243, 15-23.	2.7	117
107	Reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Nature Reviews Cardiology</i> , 2018, 15, 273-281.	6.1	116
108	Evolving use of new oral anticoagulants for treatment of venous thromboembolism. <i>Blood</i> , 2014, 124, 1020-1028.	0.6	114

#	ARTICLE	IF	CITATIONS
109	Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. <i>Circulation</i> , 2005, 111, 1390-1397.	1.6	113
110	Clinical Utility of a Rapid Whole-Blood D-Dimer Assay in Patients with Cancer Who Present with Suspected Acute Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 1999, 131, 417.	2.0	113
111	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. <i>Lancet Haematology</i> , 2017, 4, e105-e113.	2.2	112
112	New antithrombotic agents. <i>Lancet</i> , 1999, 353, 1431-1436.	6.3	111
113	Vimentin Exposed on Activated Platelets and Platelet Microparticles Localizes Vitronectin and Plasminogen Activator Inhibitor Complexes on Their Surface. <i>Journal of Biological Chemistry</i> , 2002, 277, 7529-7539.	1.6	108
114	Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non-Q-Wave Myocardial Infarction. <i>Circulation</i> , 1998, 98, 1064-1070.	1.6	107
115	Laboratory Monitoring of Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	3.0	106
116	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , 2020, 136, 1433-1441.	0.6	106
117	Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. <i>Circulation</i> , 2012, 126, 2428-2432.	1.6	105
118	Increased Neutrophil Elastase Activity in Cigarette Smokers. <i>Annals of Internal Medicine</i> , 1987, 107, 680.	2.0	104
119	Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. <i>Blood</i> , 2008, 112, 4432-4436.	0.6	103
120	Thrombosis: A Major Contributor to Global Disease Burden. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 724-735.	1.5	103
121	G-Protein-Coupled Receptors as Signaling Targets for Antiplatelet Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 449-457.	1.1	102
122	New oral anticoagulants in development. <i>Thrombosis and Haemostasis</i> , 2010, 103, 62-70.	1.8	101
123	The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro. <i>Thrombosis and Haemostasis</i> , 1998, 80, 413-417.	1.8	100
124	Evidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin. <i>Journal of Biological Chemistry</i> , 1997, 272, 25493-25499.	1.6	98
125	Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. <i>American Journal of Cardiology</i> , 1998, 82, 12P-18P.	0.7	98
126	Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins. <i>Thrombosis and Haemostasis</i> , 1993, 70, 625-630.	1.8	97



#	ARTICLE	IF	CITATIONS
127	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	2.0	96
128	Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. <i>New England Journal of Medicine</i> , 2019, 380, 1825-1833.	13.9	96
129	COVID-19 coagulopathy, thrombosis, and bleeding. <i>Blood</i> , 2020, 136, 381-383.	0.6	96
130	Novel oral anticoagulants in gastroenterology practice. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 227-239.	0.5	94
131	Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Chest</i> , 2001, 119, 321S-336S.	0.4	93
132	Emerging anticoagulants for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 96, 274-284.	1.8	93
133	The status of new anticoagulants. <i>British Journal of Haematology</i> , 2006, 134, 3-19.	1.2	92
134	Oral Direct Factor Xa Inhibitors. <i>Circulation Research</i> , 2012, 111, 1069-1078.	2.0	92
135	Delayed but not Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine Model of Sepsis. <i>Shock</i> , 2015, 44, 166-172.	1.0	92
136	Inferior Vena Cava Ligation Rapidly Induces Tissue Factor Expression and Venous Thrombosis in Rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 863-869.	1.1	90
137	Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1090-1096.	1.8	89
138	Zinc: An important cofactor in haemostasis and thrombosis. <i>Thrombosis and Haemostasis</i> , 2013, 109, 421-430.	1.8	89
139	Molecular Basis for the Susceptibility of Fibrin-bound Thrombin to Inactivation by Heparin Cofactor II in the Presence of Dermatan Sulfate but Not Heparin. <i>Journal of Biological Chemistry</i> , 2001, 276, 20959-20965.	1.6	88
140	Meeting the Unmet Needs in Anticoagulant Therapy. <i>European Journal of Haematology</i> , 2010, 85, 1-28.	1.1	87
141	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
142	An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces. <i>Scientific Reports</i> , 2017, 7, 11639.	1.6	86
143	Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. <i>Blood</i> , 2011, 118, 6667-6674.	0.6	83
144	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.	2.7	83

#	ARTICLE	IF	CITATIONS
145	Lubricant-Infused Surfaces with Built-In Functional Biomolecules Exhibit Simultaneous Repellency and Tunable Cell Adhesion. <i>ACS Nano</i> , 2018, 12, 10890-10902.	7.3	83
146	New developments in anticoagulants: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1283-1288.	1.8	81
147	Contribution of Host-Derived Tissue Factor to Tumor Neovascularization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1975-1981.	1.1	79
148	Edoxaban for treatment of venous thromboembolism in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1268-1276.	1.8	79
149	Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents. <i>Stroke</i> , 2017, 48, 1432-1437.	1.0	79
150	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. <i>Journal of the American Heart Association</i> , 2015, 4, e002322.	1.6	78
151	Factor XI Inhibition to Uncouple Thrombosis From Hemostasis. <i>Journal of the American College of Cardiology</i> , 2021, 78, 625-631.	1.2	78
152	Antithrombotic Agents. <i>Circulation Research</i> , 2019, 124, 426-436.	2.0	76
153	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	1.8	76
154	Selective D-Dimer Testing for Diagnosis of a First Suspected Episode of Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2013, 158, 93.	2.0	73
155	Exosites 1 and 2 Are Essential for Protection of Fibrin-bound Thrombin from Heparin-catalyzed Inhibition by Antithrombin and Heparin Cofactor II. <i>Journal of Biological Chemistry</i> , 1999, 274, 6226-6233.	1.6	72
156	Use of a Fixed Activated Partial Thromboplastin Time Ratio to Establish a Therapeutic Range for Unfractionated Heparin. <i>Archives of Internal Medicine</i> , 2001, 161, 385.	4.3	72
157	Single and multi-functional coating strategies for enhancing the biocompatibility and tissue integration of blood-contacting medical implants. <i>Biomaterials</i> , 2020, 258, 120291.	5.7	72
158	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. <i>Blood Advances</i> , 2018, 2, 788-796.	2.5	71
159	Homocysteine-dependent Alterations in Mitochondrial Gene Expression, Function and Structure. <i>Journal of Biological Chemistry</i> , 1998, 273, 30808-30817.	1.6	69
160	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. <i>Blood</i> , 1999, 93, 1231-1236.	0.6	69
161	Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study. <i>Thrombosis and Haemostasis</i> , 2001, 85, 390-394.	1.8	69
162	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	1.2	69

#	ARTICLE	IF	CITATIONS
163	Factors XI and XII as Targets for New Anticoagulants. <i>Frontiers in Medicine</i> , 2017, 4, 19.	1.2	69
164	Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. <i>Acta Biomaterialia</i> , 2012, 8, 4092-4100.	4.1	68
165	In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. <i>Thrombosis Research</i> , 2002, 107, 241-244.	0.8	66
166	Evidence That Both Exosites on Thrombin Participate in Its High Affinity Interaction with Fibrin. <i>Journal of Biological Chemistry</i> , 2003, 278, 21584-21591.	1.6	66
167	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , 2019, 139, 2170-2185.	1.6	66
168	Beyond heparin and warfarin: the new generation of anticoagulants. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 271-282.	1.9	64
169	Factor Xa and thrombin as targets for new oral anticoagulants. <i>Thrombosis Research</i> , 2011, 127, S5-S12.	0.8	64
170	The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1240-1248.	1.8	64
171	Effect of Nonspecific Binding to Plasma Proteins on the Antithrombin Activities of Unfractionated Heparin, Low-Molecular-Weight Heparin, and Dermatan Sulfate. <i>Circulation</i> , 1997, 95, 118-124.	1.6	64
172	Incorporation of Vitronectin into Fibrin Clots. <i>Journal of Biological Chemistry</i> , 2002, 277, 7520-7528.	1.6	63
173	Long Range Communication between Exosites 1 and 2 Modulates Thrombin Function. <i>Journal of Biological Chemistry</i> , 2009, 284, 25620-25629.	1.6	63
174	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	0.6	62
175	Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin. <i>Journal of Biological Chemistry</i> , 2000, 275, 19788-19794.	1.6	61
176	The Asp272â€“Glu282 Region of Platelet Glycoprotein Ib $\beta$ Interacts with the Heparin-binding Site of $\beta$ -Thrombin and Protects the Enzyme from the Heparin-catalyzed Inhibition by Antithrombin III. <i>Journal of Biological Chemistry</i> , 2000, 275, 3887-3895.	1.6	61
177	Translational Success Stories. <i>Circulation Research</i> , 2012, 111, 920-929.	2.0	61
178	Factor XI and factor XII as targets for new anticoagulants. <i>Thrombosis Research</i> , 2016, 141, S40-S45.	0.8	60
179	Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2021, 174, 1420-1429.	2.0	60
180	HD1, a Thrombin-directed Aptamer, Binds Exosite 1 on Prothrombin with High Affinity and Inhibits Its Activation by Prothrombinase. <i>Journal of Biological Chemistry</i> , 2006, 281, 37477-37485.	1.6	59

#	ARTICLE	IF	CITATIONS
181	Update on heparin: what do we need to know?. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 29, 199-207.	1.0	59
182	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 295-301.	1.0	59
183	Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1113-1126.	1.8	59
184	Emerging anticoagulant strategies. <i>Blood</i> , 2017, 129, 147-154.	0.6	58
185	Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty. <i>Chest</i> , 1995, 108, 486S-501S.	0.4	56
186	The contact activation inhibitor ABO23 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2173-2184.	0.6	56
187	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. <i>Lancet Haematology</i> , 2016, 3, e228-e236.	2.2	55
188	Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator. <i>Journal of Biological Chemistry</i> , 2000, 275, 10112-10120.	1.6	54
189	Bivalent Binding to $\beta$ A $\beta$ -Fibrin Engages Both Exosites of Thrombin and Protects It from Inhibition by the Antithrombin-Heparin Complex. <i>Journal of Biological Chemistry</i> , 2008, 283, 2470-2477.	1.6	54
190	Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. <i>Blood</i> , 2011, 117, 4134-4141.	0.6	54
191	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	1.0	54
192	Oncogenes as Regulators of Tissue Factor Expression in Cancer: Implications for Tumor Angiogenesis and Anti-Cancer Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 21-30.	1.5	51
193	Novel antithrombotic strategies for treatment of venous thromboembolism. <i>Blood</i> , 2020, 135, 351-359.	0.6	51
194	Investigation of the Anticoagulant Mechanisms of a Covalent Antithrombin-Heparin Complex. <i>Journal of Biological Chemistry</i> , 1998, 273, 34730-34736.	1.6	50
195	A novel approach to thrombin inhibition. <i>Thrombosis Research</i> , 2003, 109, S17-S22.	0.8	50
196	New Anticoagulants for Treatment of Venous Thromboembolism. <i>Circulation</i> , 2004, 110, I-19-I-26.	1.6	50
197	Hypercoagulable States. <i>Critical Care Clinics</i> , 2011, 27, 933-952.	1.0	50
198	Hospitalized COVID-19 Patients and Venous Thromboembolism. <i>Circulation</i> , 2020, 142, 129-132.	1.6	50

#	ARTICLE	IF	CITATIONS
199	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3140-3147.	1.2	50
200	The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model. <i>Thrombosis and Haemostasis</i> , 1992, 68, 064-068.	1.8	50
201	The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance. <i>Translational Research</i> , 1997, 130, 649-655.	2.4	49
202	Comparison of Heparin- and Dermatan Sulfate-mediated Catalysis of Thrombin Inactivation by Heparin Cofactor II. <i>Journal of Biological Chemistry</i> , 1999, 274, 27597-27604.	1.6	49
203	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 114, 645-650.	1.8	48
204	Factor XI as a Target for New Anticoagulants. <i>Hamostaseologie</i> , 2021, 41, 104-110.	0.9	48
205	Four-Factor Prothrombin Complex Concentrate for Urgent Reversal of Vitamin K Antagonists in Patients With Major Bleeding. <i>Circulation</i> , 2013, 128, 1179-1181.	1.6	47
206	Urgent Need to Measure Effects of Direct Oral Anticoagulants. <i>Circulation</i> , 2016, 134, 186-188.	1.6	47
207	Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care. <i>Annals of Emergency Medicine</i> , 2018, 71, 314-325.e1.	0.3	47
208	Global Anticoagulant Registry in the Field – Venous Thromboembolism (GARFIELD-VTE). <i>Thrombosis and Haemostasis</i> , 2016, 116, 1172-1179.	1.8	46
209	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1673-1682.	0.7	46
210	New anticoagulants: Moving beyond the direct oral anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 20-29.	1.9	45
211	Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID-19: A single-center prospective longitudinal study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1546-1557.	1.9	45
212	New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin. <i>British Journal of Pharmacology</i> , 2005, 144, 1017-1028.	2.7	44
213	Thromboprophylaxis in surgical patients. <i>Canadian Journal of Surgery</i> , 2003, 46, 129-35.	0.5	44
214	Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. <i>Circulation</i> , 2001, 103, 643-650.	1.6	43
215	Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway. <i>Thrombosis and Haemostasis</i> , 2016, 115, 89-98.	1.8	42
216	NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. <i>American Heart Journal</i> , 2016, 177, 74-86.	1.2	42

#	ARTICLE	IF	CITATIONS
217	Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post hoc analysis of the Hokusai VTE Cancer study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1866-1874.	1.9	42
218	Advances in Antithrombotic Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 7-12.	1.1	42
219	New Anticoagulant Strategies. <i>Drugs</i> , 1994, 48, 485-497.	4.9	41
220	A Replacement for Warfarin. <i>Circulation</i> , 2007, 116, 131-133.	1.6	40
221	Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. <i>Blood</i> , 2015, 125, 2712-2719.	0.6	40
222	Thrombin/Antithrombin III Complex Formation in the Neonatal Respiratory Distress Syndrome. <i>The American Review of Respiratory Disease</i> , 1992, 145, 767-770.	2.9	39
223	Structure-Function Analyses of Thrombomodulin by Gene-Targeting in Mice: The Cytoplasmic Domain Is Not Required for Normal Fetal Development. <i>Blood</i> , 1999, 93, 3442-3450.	0.6	39
224	Mechanism of Catalysis of Inhibition of Factor IXa by Antithrombin in the Presence of Heparin or Pentasaccharide. <i>Journal of Biological Chemistry</i> , 2003, 278, 35767-35774.	1.6	39
225	Binding of Anti-GRP78 Autoantibodies to Cell Surface GRP78 Increases Tissue Factor Procoagulant Activity via the Release of Calcium from Endoplasmic Reticulum Stores. <i>Journal of Biological Chemistry</i> , 2010, 285, 28912-28923.	1.6	39
226	Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 112, 924-931.	1.8	39
227	Role of the tissue factor pathway in the biology of tumor initiating cells. <i>Thrombosis Research</i> , 2010, 125, S44-S50.	0.8	38
228	Batroxobin Binds Fibrin with Higher Affinity and Promotes Clot Expansion to a Greater Extent than Thrombin. <i>Journal of Biological Chemistry</i> , 2013, 288, 16862-16871.	1.6	38
229	Conductive Electrochemically Active Lubricant-Infused Nanostructured Surfaces Attenuate Coagulation and Enable Friction-Less Droplet Manipulation. <i>Advanced Materials Interfaces</i> , 2018, 5, 1800617.	1.9	38
230	New Antithrombotics. <i>Chest</i> , 1995, 108, 471S-485S.	0.4	37
231	Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E. <i>Journal of Biological Chemistry</i> , 1998, 273, 18292-18299.	1.6	37
232	Mechanism of Action of Plasminogen Activators. <i>Thrombosis and Haemostasis</i> , 1999, 82, 974-982.	1.8	37
233	Beyond Heparin and Aspirin. <i>Archives of Internal Medicine</i> , 2000, 160, 749.	4.3	37
234	Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. <i>Nuclear Medicine and Biology</i> , 2003, 30, 61-72.	0.3	37

#	ARTICLE	IF	CITATIONS
235	New oral anticoagulants: which one should my patient use?. Hematology American Society of Hematology Education Program, 2012, 2012, 536-540.	0.9	37
236	Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Scientific Reports, 2017, 7, 2102.	1.6	37
237	Heparan sulfate: Antithrombotic or not?. Journal of Clinical Investigation, 2003, 111, 952-954.	3.9	37
238	Effect of Fibrinogen Degradation Products and Lung Ground Substance on Surfactant Function. Neonatology, 1990, 57, 325-333.	0.9	35
239	Antithrombin-Heparin Covalent Complex. Circulation, 2002, 106, 261-265.	1.6	35
240	Thrombophilia and New Anticoagulant Drugs. Hematology American Society of Hematology Education Program, 2004, 2004, 424-438.	0.9	35
241	A High Affinity Interaction of Plasminogen with Fibrin Is Not Essential for Efficient Activation by Tissue-type Plasminogen Activator. Journal of Biological Chemistry, 2012, 287, 4652-4661.	1.6	35
242	Effects of Intermittent Pneumatic Calf Compression On Postoperative Thrombin and Plasmin Activity. Thrombosis and Haemostasis, 1986, 56, 198-201.	1.8	35
243	A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thrombosis and Haemostasis, 2010, 104, 1150-1157.	1.8	34
244	Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. Thrombosis and Haemostasis, 2019, 119, 1675-1685.	1.8	34
245	Vasoflux, a New Anticoagulant With a Novel Mechanism of Action. Circulation, 1999, 99, 682-689.	1.6	33
246	Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation. Thrombosis and Haemostasis, 2008, 100, 1058-1067.	1.8	33
247	Gastrointestinal Bleeding With Edoxaban Versus Warfarin. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e003998.	0.9	33
248	Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. Thrombosis and Haemostasis, 2019, 119, 981-991.	1.8	33
249	The contact activation system as a potential therapeutic target in patients with COVID-19. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 500-505.	1.0	33
250	Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial. Circulation, 2018, 138, 1963-1973.	1.6	32
251	Biofunctional Lubricant-Infused Vascular Grafts Functionalized with Silanized Bio-Inks Suppress Thrombin Generation and Promote Endothelialization. ACS Biomaterials Science and Engineering, 2019, 5, 6485-6496.	2.6	32
252	New Antithrombotic Agents. Chest, 1998, 114, 715S-727S.	0.4	31

#	ARTICLE	IF	CITATIONS
253	New Anticoagulant Therapy. Annual Review of Medicine, 2005, 56, 63-77.	5.0	31
254	Hypercoagulable States. Clinics in Chest Medicine, 2010, 31, 659-673.	0.8	31
255	2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 304-310.	1.1	31
256	Lubricant-Infused PET Grafts with Built-In Biofunctional Nanoprobes Attenuate Thrombin Generation and Promote Targeted Binding of Cells. Small, 2019, 15, e1905562.	5.2	31
257	Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal, 2020, 55, 1901697.	3.1	31
258	Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney International Reports, 2022, 7, 200-209.	0.4	31
259	Dabigatran and risk of myocardial infarction. Nature Reviews Cardiology, 2012, 9, 260-262.	6.1	30
260	New oral anticoagulants: A view from the laboratory. American Journal of Hematology, 2012, 87, S133-6.	2.0	30
261	Zinc promotes clot stability by accelerating clot formation and modifying fibrin structure. Thrombosis and Haemostasis, 2016, 115, 533-542.	1.8	30
262	Idarucizumab for dabigatran overdose. Clinical Toxicology, 2016, 54, 644-646.	0.8	30
263	Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients. Journal of Thrombosis and Haemostasis, 2019, 17, 1694-1706.	1.9	30
264	Activation of blood coagulation by plaque rupture: Mechanisms and prevention. American Journal of Cardiology, 1995, 75, 18B-22B.	0.7	29
265	Localization of the Thrombin-binding Domain on Prothrombin Fragment 2. Journal of Biological Chemistry, 1998, 273, 8932-8939.	1.6	29
266	Emerging Anticoagulant Drugs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1491-1500.	1.1	29
267	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology, 2016, 3, e437-e445.	2.2	29
268	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circulation Research, 2019, 124, 416-425.	2.0	29
269	Direct Thrombin Inhibitors in Cardiac Disease. Cardiovascular Toxicology, 2003, 3, 13-26.	1.1	28
270	Life-Threatening Thrombosis in Mice With Targeted Arg48-to-Cys Mutation of the Heparin-Binding Domain of Antithrombin. Circulation Research, 2003, 93, 1120-1126.	2.0	28



#	ARTICLE	IF	CITATIONS
271	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	0.6	28
272	Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2016, 116, 747-753.	1.8	28
273	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	1.8	28
274	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section Vâ€™Special Situations. <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	1.8	28
275	Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020, 3, e2022886.	2.8	28
276	Histidine-rich Glycoprotein Binds Fibrin(ogen) with High Affinity and Competes with Thrombin for Binding to the Î³â€²-Chain. <i>Journal of Biological Chemistry</i> , 2011, 286, 30314-30323.	1.6	27
277	Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery. <i>Annals of Surgery</i> , 2021, 274, e204-e211.	2.1	27
278	Measurement of Markers of Activated Coagulation in Antithrombin III Deficient Subjects. <i>Thrombosis and Haemostasis</i> , 1992, 67, 542-544.	1.8	27
279	Conformational Changes in Thrombin When Complexed by Serpins. <i>Journal of Biological Chemistry</i> , 2001, 276, 44828-44834.	1.6	26
280	Identification of Dp71 Isoforms in the Platelet Membrane Cytoskeleton. <i>Journal of Biological Chemistry</i> , 2002, 277, 47106-47113.	1.6	26
281	Mechanisms Responsible for Catalysis of the Inhibition of Factor Xa or Thrombin by Antithrombin Using a Covalent Antithrombin-Heparin Complex. <i>Journal of Biological Chemistry</i> , 2003, 278, 23398-23409.	1.6	26
282	Ximelagatran: the first oral direct thrombin inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 403-413.	1.9	26
283	HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. <i>Thrombosis and Haemostasis</i> , 2010, 103, 83-96.	1.8	26
284	Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 111, 1141-1152.	1.8	26
285	Decreased Thrombin Activity of Fibrin Clots Prepared in Cord Plasma Compared with Adult Plasma. <i>Pediatric Research</i> , 1996, 39, 826-830.	1.1	26
286	New Anticoagulants. <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 201-209.	1.0	25
287	Pharmacology and Clinical Potential of Direct Thrombin Inhibitors. <i>Current Pharmaceutical Design</i> , 2005, 11, 3877-3884.	0.9	25
288	Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease. <i>Aids</i> , 2014, 28, 1791-1796.	1.0	25

#	ARTICLE	IF	CITATIONS
289	Dabigatran etexilate for prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009, 101, 2-4.	1.8	25
290	Limited Fibrin Specificity of Tissue-type Plasminogen Activator and Its Potential Link to Bleeding. <i>Journal of Vascular and Interventional Radiology</i> , 1995, 6, 19S-23S.	0.2	24
291	Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 366-380.	1.0	24
292	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease. <i>Thrombosis and Haemostasis</i> , 2016, 115, 685-711.	1.8	24
293	North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.	0.6	24
294	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1760-1768.	1.2	24
295	Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase. <i>Journal of Biological Chemistry</i> , 2001, 276, 9755-9761.	1.6	23
296	Dabigatran Reversal with Idarucizumab. <i>New England Journal of Medicine</i> , 2017, 377, 1690-1692.	13.9	23
297	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 326-341.	1.0	23
298	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , 2021, 100, 1199-1207.	2.6	23
299	Thrombin-activable Fibrinolysis Inhibitor Attenuates (DD)E-mediated Stimulation of Plasminogen Activation by Reducing the Affinity of (DD)E for Tissue Plasminogen Activator. <i>Journal of Biological Chemistry</i> , 2000, 275, 36612-36620.	1.6	22
300	Platelet polyphosphate: the long and the short of it. <i>Blood</i> , 2017, 129, 1574-1575.	0.6	22
301	Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. <i>F1000Research</i> , 2017, 6, 985.	0.8	22
302	Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTE. <i>Thrombosis Research</i> , 2020, 191, 103-112.	0.8	22
303	Do Coagulation Screening Tests Detect Increased Generation of Thrombin and Plasmin in Sick Newborn Infants?. <i>Thrombosis and Haemostasis</i> , 1993, 69, 418-421.	1.8	22
304	Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. <i>Translational Research</i> , 1998, 132, 181-185.	2.4	21
305	Heparin and Angiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1954-1955.	1.1	21
306	Surface modification with polyethylene glycol-corn trypsin inhibitor conjugate to inhibit the contact factor pathway on blood-contacting surfaces. <i>Acta Biomaterialia</i> , 2011, 7, 4177-4186.	4.1	21

#	ARTICLE	IF	CITATIONS
307	Zn <sup>2+</sup> Mediates High Affinity Binding of Heparin to the $\hat{\pm}$ C Domain of Fibrinogen. <i>Journal of Biological Chemistry</i> , 2013, 288, 29394-29402.	1.6	21
308	Comparison of the effect of coagulation and platelet function impairments on various mouse bleeding models. <i>Thrombosis and Haemostasis</i> , 2014, 112, 412-418.	1.8	21
309	Periprocedural Management of New Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation. <i>Circulation</i> , 2014, 129, 1688-1694.	1.6	21
310	Polysiloxane Nanofilaments Infused with Silicone Oil Prevent Bacterial Adhesion and Suppress Thrombosis on Intranasal Splints. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 541-552.	2.6	21
311	Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1278-1288.	1.8	20
312	Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. <i>Thrombosis Research</i> , 2018, 162, 7-14.	0.8	20
313	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. <i>Thrombosis and Haemostasis</i> , 2020, 120, 847-856.	1.8	20
314	Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. <i>Blood</i> , 2008, 112, 33-33.	0.6	20
315	New Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 619-632.	1.5	19
316	A non-anticoagulant synthetic pentasaccharide reduces inflammation in a murine model of kidney ischemia-reperfusion injury. <i>Thrombosis and Haemostasis</i> , 2006, 96, 802-806.	1.8	19
317	Heparin Synergistically Enhances Interleukin-11 Signaling through Up-regulation of the MAPK Pathway. <i>Journal of Biological Chemistry</i> , 2006, 281, 20780-20787.	1.6	19
318	The Real Decoy. <i>Circulation Research</i> , 2013, 113, 954-957.	2.0	19
319	Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2377-2387.	1.9	19
320	Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2801-2813.	1.9	19
321	Heparan sulfate: Antithrombotic or not?. <i>Journal of Clinical Investigation</i> , 2003, 111, 952-954.	3.9	19
322	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	18
323	Modes and consequences of thrombin's interaction with fibrin. <i>Biophysical Chemistry</i> , 2004, 112, 277-284.	1.5	18
324	Real world™ use of non-vitamin K antagonist oral anticoagulants (NOACs): Lessons from the Dresden NOAC Registry. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1159-1161.	1.8	18

#	ARTICLE	IF	CITATIONS
325	Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1001-1008.	1.8	18
326	Non-Vitamin K Antagonist Oral Anticoagulants. <i>Chest</i> , 2014, 145, 1177-1178.	0.4	17
327	Anticoagulation for Mechanical Heart Valves. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 743-745.	1.1	17
328	Unanswered questions in venous thromboembolism. <i>Thrombosis Research</i> , 2009, 123, S2-S10.	0.8	16
329	The mTORC Pathway in the Antiphospholipid Syndrome. <i>New England Journal of Medicine</i> , 2014, 371, 369-371.	13.9	16
330	Factor XI Antisense Oligonucleotide for Venous Thrombosis. <i>New England Journal of Medicine</i> , 2015, 372, 1671-1672.	13.9	16
331	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 809-816.	1.8	16
332	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1159-1164.	1.8	16
333	Appropriate Apixaban Dosing. <i>JAMA Cardiology</i> , 2016, 1, 635.	3.0	16
334	Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials. <i>Thrombosis and Haemostasis</i> , 2020, 120, 515-524.	1.8	16
335	Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.	0.7	16
336	Molecular Basis for the Resistance of Fibrin-Bound Thrombin to Inactivation by Heparin/Serpin Complexes. <i>Advances in Experimental Medicine and Biology</i> , 1997, 425, 55-66.	0.8	16
337	Low-dose warfarin in rehabilitating stroke survivors. <i>Thrombosis Research</i> , 2002, 107, 287-290.	0.8	15
338	Antithrombotic Activity of the Novel Oral Anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in Animal Models. <i>Thrombosis Research</i> , 2010, 126, e383-e388.	0.8	15
339	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	0.4	15
340	Factor XIII Prevents Pulmonary Emboli in Mice by Stabilizing Deep Vein Thrombi. <i>Thrombosis and Haemostasis</i> , 2019, 119, 992-999.	1.8	15
341	Mortality Risk Profiles for Sepsis: A Novel Longitudinal and Multivariable Approach. , 2019, 1, e0032.		15
342	Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation. <i>Annals of Thoracic Surgery</i> , 2020, 110, 582-590.	0.7	15

#	ARTICLE	IF	CITATIONS
343	Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. <i>Blood</i> , 2013, 122, 211-211.	0.6	15
344	Expanding use of new oral anticoagulants. <i>F1000prime Reports</i> , 2014, 6, 93.	5.9	15
345	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	3.0	15
346	The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. <i>British Journal of Haematology</i> , 1991, 79, 296-301.	1.2	14
347	Antithrombins: Their Potential as Antithrombotic Agents. <i>Annual Review of Medicine</i> , 1992, 43, 9-16.	5.0	14
348	Potential of new anticoagulants in patients with cancer. <i>Thrombosis Research</i> , 2010, 125, S30-S35.	0.8	14
349	By Increasing the Affinity of Heparin for Fibrin, Zn <sup>2+</sup> Promotes the Formation of a Ternary Heparin-Thrombin-Fibrin Complex That Protects Thrombin from Inhibition by Antithrombin. <i>Biochemistry</i> , 2012, 51, 7964-7973.	1.2	14
350	Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits. <i>Thrombosis and Haemostasis</i> , 2014, 112, 79-86.	1.8	14
351	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. <i>Thrombosis Research</i> , 2017, 149, 29-37.	0.8	14
352	Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation. <i>TH Open</i> , 2018, 02, e190-e201.	0.7	14
353	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 20-29.	1.0	14
354	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 201, 63-72.	0.8	14
355	Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3031-3043.	1.9	14
356	Incorporation of Fragment X into Fibrin Clots Renders Them More Susceptible to Lysis by Plasmin. <i>Biochemistry</i> , 2006, 45, 4257-4265.	1.2	13
357	Initial treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 96, 242-250.	1.8	13
358	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ: British Medical Journal</i> , 2011, 342, c7270-c7270.	2.4	13
359	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 944-950.e3.	0.4	13
360	Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 040-050.	0.8	13

#	ARTICLE	IF	CITATIONS
361	Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. <i>European Journal of Haematology</i> , 2018, 101, 3-11.	1.1	13
362	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.	1.9	13
363	FIBRIN CLOT LYSIS BY TISSUE PLASMINOGEN ACTIVATOR (tPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1995, 60, 144-146.	0.5	13
364	Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery. , 2022, 1, .		13
365	Selective factor Xa inhibition for thromboprophylaxis. <i>Lancet, The</i> , 2008, 372, 6-8.	6.3	12
366	Modification of Polyurethane with Polyethylene Glycol-Corn Trypsin Inhibitor for Inhibition of Factor Xlla in Blood Contact. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2012, 23, 1981-1993.	1.9	12
367	Targeted Gene Sequencing Identifies Variants in the Protein C and Endothelial Protein C Receptor Genes in Patients With Unprovoked Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2674-2681.	1.1	12
368	Anticoagulation therapy in 2015: where we are and where we are going. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 264-272.	1.0	12
369	Advances in Thrombosis and Hemostasis. <i>Circulation Research</i> , 2016, 118, 1337-1339.	2.0	12
370	Exosite 2-Directed Ligands Attenuate Protein C Activation by the Thrombin-Thrombomodulin Complex. <i>Biochemistry</i> , 2017, 56, 3119-3128.	1.2	12
371	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. <i>Thrombosis and Haemostasis</i> , 2018, 118, S23-S33.	1.8	12
372	Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function. <i>PLoS ONE</i> , 2016, 11, e0157471.	1.1	12
373	Interaction of low molecular weight heparin with ketorolac. <i>Translational Research</i> , 1996, 127, 583-587.	2.4	11
374	Dual surface modification with PEG and corn trypsin inhibitor: Effect of PEG:CTI ratio on protein resistance and anticoagulant properties. <i>Journal of Biomedical Materials Research - Part A</i> , 2012, 100A, 856-862.	2.1	11
375	Procoagulants for management of bleeding with the new oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2013, 110, 01.	1.8	11
376	Transition from apixaban to warfarin-addressing excess stroke, systemic embolism, and major bleeding. <i>American Heart Journal</i> , 2015, 169, 1-3.	1.2	11
377	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 257-270.	1.8	11
378	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. <i>Thrombosis Research</i> , 2018, 168, 121-129.	0.8	11

#	ARTICLE	IF	CITATIONS
379	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 431-497.	1.0	11
380	Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. Thrombosis and Haemostasis, 2019, 119, 689-694.	1.8	11
381	Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial. Thrombosis and Haemostasis, 2019, 119, 461-466.	1.8	11
382	Activated thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates fibrin-dependent plasmin generation on thrombin-activated platelets. Journal of Thrombosis and Haemostasis, 2020, 18, 2364-2376.	1.9	11
383	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. Critical Reviews in Oncology/Hematology, 2021, 157, 103125.	2.0	11
384	Polyphosphate-induced thrombosis in mice is factor XII dependent and is attenuated by histidine-rich glycoprotein. Blood Advances, 2021, 5, 3540-3551.	2.5	11
385	Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants. Polish Archives of Internal Medicine, 2016, 126, 688-696.	0.3	11
386	Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?. TH Open, 2020, 04, e446-e456.	0.7	11
387	Immunothrombosis Biomarkers for Distinguishing Coronavirus Disease 2019 Patients From Noncoronavirus Disease Septic Patients With Pneumonia and for Predicting ICU Mortality. , 2021, 3, e0588.		11
388	State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. Thrombosis and Haemostasis, 2022, 122, 1279-1287.	1.8	11
389	Importance of Family History as a Risk Factor for Venous Thromboembolism. Circulation, 2011, 124, 996-997.	1.6	10
390	Reduced Plasminogen Binding and Delayed Activation Render $\beta$ -Fibrin More Resistant to Lysis than $\beta$ A-Fibrin. Journal of Biological Chemistry, 2014, 289, 27494-27503.	1.6	10
391	Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2338-2344.	1.1	10
392	Identification and characterization of a factor Va-binding site on human prothrombin fragment 2. Scientific Reports, 2019, 9, 2436.	1.6	10
393	Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1661-1671.	1.9	10
394	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 1-11.	1.0	10
395	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. Journal of Thrombosis and Haemostasis, 2021, 19, 3008-3017.	1.9	10
396	Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis. Thrombosis and Haemostasis, 1991, 65, 541-544.	1.8	10

#	ARTICLE	IF	CITATIONS
397	Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: Results of the VITAL study (Vasoflux International) Tj ETQq1 1 0.784314 rgBT /@verlock	1.4	11
398	Glycosaminoglycans Bind Factor Xa in a Ca <sup>2+</sup> -Dependent Fashion and Modulate Its Catalytic Activity. Biochemistry, 2003, 42, 13091-13098.	1.2	9
399	Dabigatran monitoring made simple?. Thrombosis and Haemostasis, 2013, 110, 393-395.	1.8	9
400	A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. Thrombosis and Haemostasis, 2016, 116, 241-250.	1.8	9
401	Addressing the burden of hospital-related venous thromboembolism: the role of extended anticoagulant prophylaxis. Journal of Thrombosis and Haemostasis, 2018, 16, 413-417.	1.9	9
402	Global public awareness about atrial fibrillation. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 49-57.	1.0	9
403	Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. Circulation Research, 2019, 124, 351-353.	2.0	9
404	The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thrombosis Research, 2021, 203, 155-162.	0.8	9
405	Inhibition of osteolytic bone metastasis by unfractionated heparin. Clinical and Experimental Metastasis, 2008, 25, 903-911.	1.7	8
406	Otamixaban in acute coronary syndromes. Lancet, The, 2009, 374, 762-764.	6.3	8
407	Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials. Thrombosis and Haemostasis, 2016, 116, S33-S40.	1.8	8
408	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	1.8	8
409	Overview of Hemostasis and Thrombosis. , 2018, , 1831-1842.		8
410	Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition. Thrombosis Research, 2019, 184, 44-49.	0.8	8
411	MAA868 locks factor XIa in a zymogen-like state. Blood, 2019, 133, 1393-1394.	0.6	8
412	Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study. Blood, 2019, 134, 163-163.	0.6	8
413	Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. Journal of Thrombosis and Haemostasis, 2021, , .	1.9	8
414	Producing Fluorine- and Lubricant-Free Flexible Pathogen- and Blood-Repellent Surfaces Using Polysiloxane-Based Hierarchical Structures. ACS Applied Materials & Interfaces, 2022, 14, 3864-3874.	4.0	8



#	ARTICLE	IF	CITATIONS
415	New oral anticoagulants: which one should my patient use?. Hematology American Society of Hematology Education Program, 2012, 2012, 536-40.	0.9	8
416	Localization of heparin and low-molecular-weight heparin in the rat kidney. Thrombosis and Haemostasis, 2004, 91, 927-934.	1.8	7
417	Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis. Thrombosis and Haemostasis, 2009, 102, 1212-1218.	1.8	7
418	Genetics of Coagulation: What the Cardiologist Needs to Know. Canadian Journal of Cardiology, 2013, 29, 75-88.	0.8	7
419	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. Canadian Journal of Cardiology, 2016, 32, 1332-1339.	0.8	7
420	Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE ADâ„¢ study. Journal of Medical Economics, 2017, 20, 435-442.	1.0	7
421	AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 533-535.	1.1	7
422	Rivaroxaban for prevention and treatment of venous thromboembolism. Future Cardiology, 2019, 15, 63-77.	0.5	7
423	Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial. Thrombosis and Haemostasis, 2021, 121, 1684-1695.	1.8	7
424	Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism. Thrombosis and Haemostasis, 1996, 75, 551-554.	1.8	7
425	Hypercoagulability and coronavirus disease 2019â€™ associated hypoxemic respiratory failure: Mechanisms and emerging management paradigms. Journal of Trauma and Acute Care Surgery, 2020, 89, e177-e181.	1.1	7
426	Dysfibrinogenemia in Obstructive Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 1987, 6, 967-970.	0.9	6
427	Antithrombin-Independent Anticoagulation by Hypersulfated Low-Molecular-Weight Heparin. Trends in Cardiovascular Medicine, 2002, 12, 281-287.	2.3	6
428	Emerging therapies for stroke prevention in atrial fibrillation. Country Review Ukraine, 2005, 7, C19-C27.	0.8	6
429	Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. Thrombosis and Haemostasis, 2010, 103, 481-483.	1.8	6
430	Warfarin After Bioprosthetic Aortic Valve Implantation. JAMA - Journal of the American Medical Association, 2012, 308, 2147.	3.8	6
431	Ciraparantag for enoxaparin reversal: Adding to the evidence. Thrombosis Research, 2016, 146, 106-107.	0.8	6
432	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with bioprosthetic valves. Expert Review of Cardiovascular Therapy, 2018, 16, 413-418.	0.6	6

#	ARTICLE	IF	CITATIONS
433	Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1116-1119.	0.8	6
434	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986364.	1.0	6
435	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 12-19.	1.0	6
436	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high and low dose rivaroxaban with aspirin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 308-313.	1.0	6
437	The Additive Effect of Low Molecular Weight Heparins on Thrombin Inhibition by Dermatan Sulfate. <i>Thrombosis and Haemostasis</i> , 1993, 70, 443-447.	1.8	6
438	In the Presence of Phospholipids, Glycosaminoglycans Potentiate Factor Xa-Mediated Protein C Activation by Modulating Factor Xa Activity. <i>Biochemistry</i> , 2007, 46, 4195-4203.	1.2	5
439	Anticoagulation for ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2009, 119, 1186-1188.	1.6	5
440	New and Emerging Anticoagulant Therapies for Venous Thromboembolism. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 142-155.	0.4	5
441	More on Acutely Injured Patients Receiving Dabigatran. <i>New England Journal of Medicine</i> , 2012, 366, 863-864.	13.9	5
442	The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand. <i>BMC Biochemistry</i> , 2013, 14, 6.	4.4	5
443	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. <i>TH Open</i> , 2018, 02, e1-e7.	0.7	5
444	Antithrombotic Drugs. , 2018, , 2168-2188.		5
445	Abstract 17392: Gastrointestinal Bleeding With Edoxaban versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial. <i>Circulation</i> , 2015, 132, .	1.6	5
446	Recent advances in understanding, diagnosing and treating venous thrombosis. <i>F1000Research</i> , 2020, 9, 1206.	0.8	5
447	Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 695-706.	1.4	5
448	Development and Application of Assays for Elastase-Specific Fibrinogen Fragments. <i>Annals of the New York Academy of Sciences</i> , 1991, 624, 154-166.	1.8	4
449	Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). <i>Thrombosis Research</i> , 2015, 136, S13-S18.	0.8	4
450	An open-label study of the pharmacokinetics and pharmacodynamics of dabigatran etexilate 150 mg once daily in Caucasian patients with moderate renal impairment undergoing primary unilateral elective total knee or hip replacement surgery. <i>Thrombosis Research</i> , 2016, 144, 158-164.	0.8	4

#	ARTICLE	IF	CITATIONS
451	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018, 170, 75-83.	0.8	4
452	Randomized phase 2 trial comparing JNJ-375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2081-2088.	1.9	4
453	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2772-2780.	1.9	4
454	Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism. <i>Blood</i> , 2018, 132, 2527-2527.	0.6	4
455	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. <i>Blood</i> , 2012, 120, LBA-1-LBA-1.	0.6	4
456	Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. <i>Blood</i> , 2014, 124, 1543-1543.	0.6	4
457	Transparent and Highly Flexible Hierarchically Structured Polydimethylsiloxane Surfaces Suppress Bacterial Attachment and Thrombosis Under Static and Dynamic Conditions. <i>Small</i> , 2022, 18, e2108112.	5.2	4
458	New anticoagulant drugs. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 12, 7-17.	1.0	3
459	Prevention and treatment of venous thromboembolism during pregnancy. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, S22-6.	0.7	3
460	Vorapaxar, Combination Antiplatelet Therapy, and Stroke—. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2327-2329.	1.2	3
461	A PoTENTIAL Antidote. <i>Circulation Research</i> , 2016, 119, 1157-1160.	2.0	3
462	Are Ticks the Answer to Medical Device-Associated Clotting?. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2190-2192.	1.2	3
463	Ciraparantag as a potential universal anticoagulant reversal agent. <i>European Heart Journal</i> , 2022, 43, 993-995.	1.0	3
464	Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2021, 0, .	1.8	3
465	Identification of the histidine-rich glycoprotein domains responsible for contact pathway inhibition. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 821-832.	1.9	3
466	Acute coronary syndromes: a focus on thrombin. <i>Journal of Invasive Cardiology</i> , 2002, 14 Suppl B, 2B-7B.	0.4	3
467	Elevated Fibrinopeptide A and B Levels during Thrombolytic Therapy: Real or Artefactual?. <i>Thrombosis and Haemostasis</i> , 1996, 75, 529-535.	1.8	2
468	The new heparins. <i>Coronary Artery Disease</i> , 1998, 9, 65-74.	0.3	2

#	ARTICLE	IF	CITATIONS
469	Emerging themes in the treatment of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2006, 96, 239-241.	1.8	2
470	Emerging Anticoagulant Drugs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 721-721.	1.1	2
471	Idrabiotaparinux treatment for venous thromboembolism. <i>Lancet, The</i> , 2012, 379, 96-98.	6.3	2
472	Assessment and Management of Gastrointestinal Hemorrhage in the Setting of Direct Oral Anticoagulants: The Hematology Perspective. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 29-35.	0.7	2
473	Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017, 376, 2491-2492.	13.9	2
474	Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1509-1517.	1.8	2
475	Hematologic Problems in the Surgical Patient. , 2018, , 2304-2312.e4.		2
476	Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy" <i>Circulation Research</i> , 2019, 124, e119.	2.0	2
477	Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Blood</i> , 2020, 136, 23-24.	0.6	2
478	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 266-284.	0.9	2
479	Deep vein thrombosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 1999, 1, 43-53.	0.4	1
480	Neutrophils and the protein C pathway. <i>Blood</i> , 2003, 102, 1152-1153.	0.6	1
481	OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 478-479.	3.3	1
482	Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? <i>American Journal of Emergency Medicine</i> , 2014, 32, 1433-1434.	0.7	1
483	Measuring Dabigatran Levels: What Tests Are Available and What Still Needs to Be Done?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2213-2214.	1.8	1
484	Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. <i>Blood Advances</i> , 2018, 2, 1806-1806.	2.5	1
485	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. <i>Haematologica</i> , 2019, 104, e474-e477.	1.7	1
486	Zinc Enhances the Protection of Fibrin-Bound Thrombin from Antithro Inhibition.. <i>Blood</i> , 2007, 110, 2691-2691.	0.6	1

#	ARTICLE	IF	CITATIONS
487	Ximelagatran: the first oral direct thrombin inhibitor. , 0, .		1
488	Zinc <sup>2+</sup> Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes.. Blood, 2005, 106, 1956-1956.	0.6	1
489	A Histomorphometric Evaluation of Heparin-Induced Bone Loss After Discontinuation of Heparin Treatment in Rats. Blood, 1999, 93, 1231-1236.	0.6	1
490	Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open, 2022, 06, e177-e183.	0.7	1
491	Management of Venous Thromboembolism: Present and Future. Circulation, 2004, 110, 1-2-1-2.	1.6	0
492	Changing Paradigms in the Management of Venous Thromboembolism. The American Heart Hospital Journal, 2006, 4, 135-141.	0.2	0
493	Should Warfarin Be Restarted After Warfarin-Associated Intracranial Hemorrhage?. Canadian Journal of Cardiology, 2012, 28, 6-8.	0.8	0
494	Venous Thrombosis. , 2013, , 619-626.		0
495	792 Do Concurrent Gastroprotective Agents Impact Gastrointestinal Bleeding Rates in Edoxaban Users? Results From the ENGAGE-AF TIMI 48 Trial. Gastroenterology, 2016, 150, S165.	0.6	0
496	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants" Circulation, 2016, 134, e498.	1.6	0
497	Letter to the Editor. Journal of Intensive Care Medicine, 2016, 31, 70-71.	1.3	0
498	Evaluation of direct oral anticoagulants in superficial-vein thrombosis " Authors' reply. Lancet Haematology,the, 2017, 4, e254-e255.	2.2	0
499	Research and Practice in Thrombosis and Haemostasis - a new ISTH publishing platform for the global thrombosis and hemostasis community. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 6-8.	1.0	0
500	In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. Annals of Internal Medicine, 2017, 167, JC17.	2.0	0
501	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. Blood Advances, 2018, 2, 3193-3195.	2.5	0
502	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications. , 2019, , 1067-1077.		0
503	International Society on Thrombosis and Haemostasis: Present and future. Journal of Thrombosis and Haemostasis, 2021, 19, 1599-1601.	1.9	0
504	Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology American Society of Hematology Education Program, 2000, 2000, 266-284.	0.9	0

#	ARTICLE	IF	CITATIONS
505	Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin.. Blood, 2004, 104, 1721-1721.	0.6	0
506	Studies into the Mechanism by Which Glycosaminoglycans Potentiate Protein C Activation by Factor Xa.. Blood, 2004, 104, 1724-1724.	0.6	0
507	No Fibrinolytic Benefit of Adjunctive Anticoagulation during Arterial Thrombolysis Induced by tPA Combined with TAFIa Inhibitor in a Rabbit Arterial Thrombosis Model.. Blood, 2004, 104, 2979-2979.	0.6	0
508	Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA.. Blood, 2004, 104, 1737-1737.	0.6	0
509	Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin.. Blood, 2005, 106, 1950-1950.	0.6	0
510	Factor V Binding to Multimerin 1: Modulation by Factor V Activation and Binding Sites in the Factor V C1 and C2 Domains.. Blood, 2006, 108, 193-193.	0.6	0
511	Laboratory assessment of platelet function and coagulation. , 2008, , 19-31.		0
512	Overview of New Anticoagulant Drugs. Fundamental and Clinical Cardiology, 2009, , 133-154.	0.0	0
513	New Antithrombotic Drugs: Beyond Aspirin and Heparin. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 68-68.	0.5	0
514	Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. Blood, 2014, 124, LBA-1-LBA-1.	0.6	0
515	Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thromboprophylaxis. Blood, 2018, 132, 1236-1236.	0.6	0
516	Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial. Blood, 2019, 134, 3669-3669.	0.6	0
517	Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study. Blood, 2021, 133, 3024-3024.	0.6	0
518	Extended treatment of venous thromboembolism. Clinical Advances in Hematology and Oncology, 2013, 11, 302-4.	0.3	0
519	ISTH Biennial Impact Report: Looking back and looking forward. Journal of Thrombosis and Haemostasis, 2022, 20, 1515-1517.	1.9	0
520	Trends in the proportion of women as reviewers, editors, and editorial board members of 15 North American and British medical journals from 2014 to 2019: A retrospective study. European Science Editing, 0, 48, .	0.0	0